# A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

> **NCT06015308** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 224 (actual)

## Conditions studied

- Dermatitis Atopic

## Interventions

- **DRUG:** Amlitelimab
- **DRUG:** Placebo
- **BIOLOGICAL:** Tdap vaccine
- **BIOLOGICAL:** PPS vaccine

## Key facts

- **NCT ID:** NCT06015308
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-06
- **Primary completion:** 2025-10-01
- **Final completion:** 2026-01-16
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015308, "A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06015308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*